LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aktien・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

75.45 -0.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

75.06

Max

77.09

Schlüsselkennzahlen
By Trading Economics
Einkommen	136M -93M
Verkäufe	43M 246M
EPS	-0.303
Gewinnspanne	-37.599
Angestellte	1,402
EBITDA	-4.7B -117M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+38.91% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	516M 12B
Vorheriger Eröffnungskurs	76.17
Vorheriger Schlusskurs	75.45

Nachrichtenstimmung

By Acuity

50%

166 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

29.78 / 33.645 Unterstützung & Widerstand

Ionis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Ionis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

38.91% Vorteil

12-Monats-Prognose

Durchschnitt 105.6 USD 38.91%

Hoch 130 USD

Tief 72 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ionis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

Buy

Halten

Sell

Basierend auf 17 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ionis Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.78 / 33.645Unterstützung & Widerstand

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

166 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.